ArticleFrontiers in pharmacology2025
Sanhuang Fukang oil alleviates X-ray-induced skin injury by reducing inflammation and apoptosis: an
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiation dermatitis is a significant dose-limiting toxicity of radiotherapy that compromises treatment efficacy and patient quality of life. Although topical anti-inflammatory agents and emollients provide symptomatic relief, they fail to address the underlying pathophysiological mechanisms. SHFKO, a botanical extract with documented antioxidant and anti-inflammatory properties, has been used in traditional medicine but its molecular mechanisms of action remain poorly characterized. This study systematically investigated the therapeutic potential of SHFKO in mitigating radiation-induced skin injury through integrated chemical, molecular, and histopathological analyses. Methods: Ultra-performance liquid chromatography (UPLC) was used to characterize the bioactive components of SHFKO. A mouse model of radiodermatitis was monitored for cutaneous manifestations and healing. Expression levels of inflammatory mediators (MMP13, IL-6, IL-1β), antioxidant enzymes (catalase, HO-1, SOD-1, Nrf2), and apoptotic regulators (cleaved-caspase 3, Bcl-2) were measured using RT-PCR and Western blotting to assess radiation-induced oxidative stress and apoptosis. The effects of SHFKO on MAPK/NF-κB/PI3K-AKT signaling pathways were evaluated by Western blotting and immunohistochemistry. Results: UPLC analysis confirmed a diverse bioactive profile of SHFKO. Conclusion: This study demonstrated significant therapeutic effects of SHFKO in treating radiodermatitis, characterized by accelerated healing of acute radiation-induced cutaneous injuries. The multi-targeted mechanisms involved apoptosis inhibition, reduction of pro-inflammatory mediators, MAPK/PI3K-AKT pathway inhibition, and restoration of ROS homeostasis. These findings suggest SHFKO as a promising candidate for clinical development in radiation dermatitis treatment, offering a multi-target therapeutic approach distinct from conventional approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.